Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CHF 2819 is a novel orally active acetylcholinesterase inhibitor (AChE) developed for the treatment of Alzheimer's disease (AD). CHF 2819 is a selective inhibitor of AChE, it is 115 times more potent against this enzyme than against butyrylcholinesterase (BuChE).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,820.00 | |
50 mg | 8-10 weeks | $ 2,380.00 | |
100 mg | 8-10 weeks | $ 3,100.00 |
Description | CHF 2819 is a novel orally active acetylcholinesterase inhibitor (AChE) developed for the treatment of Alzheimer's disease (AD). CHF 2819 is a selective inhibitor of AChE, it is 115 times more potent against this enzyme than against butyrylcholinesterase (BuChE). |
Synonyms | Ganstigmine HCl, CHF-2819, Ganstigmine hydrochloride, CHF2819 |
Molecular Weight | 403.9 |
Formula | C21H26ClN3O3 |
CAS No. | 412044-92-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CHF 2819 412044-92-9 Ganstigmine Hydrochloride Ganstigmine HCl CHF-2819 Ganstigmine hydrochloride CHF2819 inhibitor inhibit